Your browser doesn't support javascript.
loading
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Roncolato, F T; O'Connell, R L; Joly, F; Lanceley, A; Hilpert, F; Buizen, L; Okamoto, A; Aotani, E; Salutari, V; Donnellan, P; Oza, A; Avall-Lundqvist, E; Berek, J; Fehm, T; Ledermann, J; Roemer-Becuwe, C; Stockler, M R; King, M T; Friedlander, M L.
Afiliación
  • Roncolato FT; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Macarthur Cancer Therapy Centre, Campbelltown, Australia; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia. Electronic address: felicia.roncolato@ctc.usyd.edu.au.
  • O'Connell RL; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Joly F; Centre Francois Baclesse, Caen, GINECO Intergroup, France.
  • Lanceley A; University College London, London, United Kingdom.
  • Hilpert F; AGO Study Group and Onkologisches Therapiezentrum Hamburg am Krankenhaus Jerusalem, GermanyThe Jikei University School of Medicine, Japan.
  • Buizen L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Okamoto A; Kitasato Academic Research Organisation, Japan.
  • Aotani E; Kitasato University, Graduate School of Nursing, Tokyo, Japan.
  • Salutari V; Catholic University of the Sacred Heart, Milano, Lombardia, Italy.
  • Donnellan P; Galway University Hospital, Ireland; All-Ireland Oncology Research Group (ICORG), Ireland.
  • Oza A; Princess Margaret Hospital, Canada.
  • Avall-Lundqvist E; Department of Oncology and Department of Clinical and Experimental Medicine, Sweden and Karolinska Institutet, Stockholm, Sweden.
  • Berek J; Stanford Women's Cancer Center, USA.
  • Fehm T; AGO Study Group and University of Duesseldorf, Department of Gynecology and Obstetrics, Duesseldorf, Germany.
  • Ledermann J; UCL Cancer Trials Centre, London, United Kingdom.
  • Roemer-Becuwe C; Cenere d'Oncologie de Gentilly, Nancy, France.
  • Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • King MT; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia; Psycho-Oncology Research Group (PoCoG), School of Psychology, Central Clinical School, Sydney Medical School, University of Sydney, Australia.
  • Friedlander ML; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia; Department of Medical Oncology, Prince of Wales Hospital, New South Wales, Australia.
Gynecol Oncol ; 156(1): 45-53, 2020 01.
Article en En | MEDLINE | ID: mdl-31836184
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_cobertura_universal Asunto principal: Neoplasias Ováricas / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_cobertura_universal Asunto principal: Neoplasias Ováricas / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2020 Tipo del documento: Article